Endpoints and statistical analysis
death
DISEASE, DISEASE PROGRESSION, SECONDARY
The mainly purpose was to assess the safety of nab‐paclitaxel in combination with radiotherapy and to confirm the phase II recommended dose. The secondary endpoints were ORR, disease control rate (DCR), progression‐free survival (PFS), and OS. Patient characteristics, treatments, and safety were evaluated by descriptive statistic method. Mean value and standard deviation were used for continuous data, while frequency and percentage distribution for discrete data. PFS was defined as time from the first dose of study treatment to the first documented disease progression per RECIST version 1.1. OS was defined as time from the first dose of study treatment to death. OS and PFS was estimated using Kaplan–Meier model. We analyzed data with Statistical Package for Social Sciences version 19.0 software.